Development of anti-cancer strategy to increase sensitivity of cancer cells to chemotherapy using siRNA combined with HVJ-E vector
Development of anti-cancer strategy to increase sensitivity of cancer cells to chemotherapy using siRNA combined with HVJ-E vector
批准号:
15300163
负责人:
KANEDA Yasufumi
金额:
$8.51万
依托单位:
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (B)
财政年份:
2003
资助国家:
日本
项目状态:
已结题
起止时间:
2003 至 2004
中文摘要
每一种癌症治疗似乎对癌症消退都是短暂有效的,但癌症会逐渐转变为对治疗产生抗性。癌症也会发展出抵抗化疗的机制。短干扰RNA(Short interfering RNA,siRNA)是通过特异性消化靶蛋白mRNA来抑制靶蛋白表达的有效工具。当与有效的递送系统结合时,使用siRNA抑制该机制可以增强癌症对化疗的敏感性。为了增强化疗的抗癌效果,我们测试了短干扰RNA(siRNA)抑制化疗耐药基因表达的能力。我们发现Rad51在癌细胞中被顺式二氨二氯铂(CDDP;顺铂)增强。Rad51的过表达导致癌细胞对CDDP产生耐药性。当使用HVJ(日本血凝病毒,仙台病毒)包膜载体将合成的Rad 51 siRNA递送至HeLa细胞时,siRNA的递送效率约为100%。在第2天没有检测到Rad51转录物,并且在siRNA转移后4天Rad51蛋白完全消失。Rad51 siRNA和CDDP的组合引起DNA损伤增加,这通过脉冲场凝胶电泳检测。当HeLa细胞在siRNA转移后与0.02 μ g/ml CDDP孵育3小时时,集落数减少至使用乱序siRNA的集落数的约10%。当使用HVJ包膜载体将Rad51 siRNA递送到肿瘤中时,递送效率约为50%,并且Rad51转录物水平降低约60%。与单独使用SiRNA或CDDP相比,Rad51 SiRNA与CDDP联合使用可显着抑制肿瘤生长。我们的结果表明,CDDP和Rad51 SiRNA联合使用将是一种有效的抗癌方案。
英文摘要
Every cancer therapy appears to be transiently effective for cancer regression, but cancers gradually transform to be resistant to the therapy. Cancers also develop machineries to resist chemotherapy. Short interfering RNA (siRNA) has been evaluated as an attractive and effective tool for suppressing target protein by specifically digesting its mRNA. Suppression of the machineries using siRNA may enhance the sensitivity to chemotherapy in cancers when combined with effective delivery system. To enhance the anti-cancer effect of chemotherapy, we tested the ability of short interfering RNA(siRNA) to inhibit chemotherapy-resistant gene expression. We found that Rad51 was enhanced with cis-diamminedichloroplatinum (II) (CDDP ; cisplatin) in cancer cells. Overexpression of Rad51 caused cancer cells to become resistant to CDDP. When synthetic Rad 51 siRNA was delivered to HeLa cells using HVJ (hemagglutinating virus of Japan, Sendai virus) envelope vector, the delivery efficiency of siRNA was approximately 100%. No Rad51 transcripts were detected on day 2, and Rad51 protein completely disappeared for 4 days after siRNA transfer. The combination of Rad51 siRNA and CDDP caused increased DNA damage, which was detected by pulsed-field gel electrophoresis. When HeLa cells were incubated with 0.02 μg/ml CDDP for 3 hours after siRNA transfer, the number of colonies decreased to approximately 10% of that with scrambled siRNA. When Rad51 siRNA was delivered into tumors using HVJ envelope vector, the delivery efficiency was approximately 50%, and the Rad51 transcript level was reduced by approximately 60%. Rad51 siRNA combined with CDDP significantly inhibited the tumor growth when compared to siRNA or CDDP alone.Our results suggest that the combination of CDDP and Rad51 siRNA will be an effective anti-cancer protocol.
期刊论文(48)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
Yamamoto, S.: "A novel combination of suicide gene therapy and histone deacetylase inhibitor for treatment of malignant melanoma"Cancer Gene Therapy. 10. 179-186 (2003)
Yamamoto, S.:“自杀基因疗法和组蛋白脱乙酰酶抑制剂的新型组合用于治疗恶性黑色素瘤”癌症基因疗法。
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
Ogushi, I.: "Nuclear factor kappa B decoy oligodeoxynucleotides prevent endotoxin-induced fatal liver failure in a murine model"Hepatology. 38. 335-344 (2003)
Ogushi, I.:“核因子 kappa B 诱饵寡脱氧核苷酸可预防小鼠模型中内毒素诱导的致命性肝衰竭”肝病学。
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
Kaneda, Y.: "Methods in ENZYMOLOGY"ELSEVIER. 596 (2003)
Kaneda, Y.:“酶学方法”ELSEVIER。
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
No influence of tumor growth by intramuscular injection of hepatocyte growth factor plasmid DNA : safety evaluation of therapeutic angiogenesis.
肌内注射肝细胞生长因子质粒 DNA 对肿瘤生长没有影响:治疗性血管生成的安全性评价。
DOI:
--
发表时间:
2004
期刊:
Biochem.Biophys.Res.Comm. 315
影响因子:
--
作者:
[Matsuki, A.]
通讯作者:
A.
Intrathecal injection of HVJ-E containing HGF gene to cerebrospinal fluid can prevent and ameliorate hearing impairement in rats.
脑脊液鞘内注射含有HGF基因的HVJ-E可预防和改善大鼠听力障碍。
DOI:
--
发表时间:
2004
期刊:
The FASEB J. 18
影响因子:
--
作者:
[Oshima, K.]
通讯作者:
K.
共 17 条
Molecular mechanism of cancer cell pluripotency responding to stress
-
批准号:24659149
-
项目类别:Grant-in-Aid for Challenging Exploratory Research
-
资助金额:$2.5万
-
财政年份:2012
-
负责人:KANEDA Yasufumi
-
依托单位:
Development of multi-lateral cancer gene therapy by enhancing anti-tumor activity of inactivated Sendai virus particle
-
批准号:22300339
-
项目类别:Grant-in-Aid for Scientific Research (B)
-
资助金额:$11.15万
-
财政年份:2010
-
负责人:KANEDA Yasufumi
-
依托单位:
Transcriptional regulation of osteogenesis using siRNA and its application to bone formation
-
批准号:17300153
-
项目类别:Grant-in-Aid for Scientific Research (B)
-
资助金额:$7.55万
-
财政年份:2005
-
负责人:KANEDA Yasufumi
-
依托单位:
Development of slow release reagent of NFkB decoy oligodeoxynucleotides for the treatment of rheumatic arthritis
-
批准号:13558109
-
项目类别:Grant-in-Aid for Scientific Research (B)
-
资助金额:$8.13万
-
财政年份:2001
-
负责人:KANEDA Yasufumi
-
依托单位:
Basic study of correction of mutated gene in xeroderma pigmentosum group A
-
批准号:10470505
-
项目类别:Grant-in-Aid for Scientific Research (B)
-
资助金额:$8.26万
-
财政年份:1998
-
负责人:KANEDA Yasufumi
-
依托单位:
Isolation and characterization of tumor-specific antigen toward cancer gene therapy
-
批准号:09044306
-
项目类别:Grant-in-Aid for international Scientific Research
-
资助金额:$2.3万
-
财政年份:1997
-
负责人:KANEDA Yasufumi
-
依托单位:
Development of new DDS to individual organs by means of cell technology and its opplication to treatment of human diseases
-
批准号:07558126
-
项目类别:Grant-in-Aid for Scientific Research (A)
-
资助金额:$6.21万
-
财政年份:1995
-
负责人:KANEDA Yasufumi
-
依托单位:
Joint Study on the Therapy of Diseases by Gene Transfer
-
批准号:05044170
-
项目类别:Grant-in-Aid for international Scientific Research
-
资助金额:$5.44万
-
财政年份:1993
-
负责人:KANEDA Yasufumi
-
依托单位:
国内基金
海外基金
登录
查看更多内容
基于聚(β-氨基酯)递送Roflumilast/siRNA复合体治疗MASLD相关肝纤维化的作用研究
-
批准号:JCZRQNB202600554
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
基于多组学联合siRNA-核酸适配体技术的骨髓增生异常综合征靶向治疗研究
-
批准号:2026JJ30092
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:张济
-
依托单位:
功能化破骨前体细胞膜递送双siRNA协同调控骨免疫和骨稳态改善骨质疏松的机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:乔方玉
-
依托单位:
核糖体RNA来源的siRNA通过调控翻译影
响植物干旱响应的机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2025
-
负责人:崔洁
-
依托单位:
膜融合型梭状核壳载体的构建及其增强siRNA胞内递释的机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:俞淼荣
-
依托单位:
基因编辑的巨噬细胞外泌体递送METTL3 siRNA增强肝癌放疗免疫的应用及机制研究
-
批准号:JCZRLH202501021
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:
-
依托单位:
RNA技术构建IGFBP3 siRNA-特异性适配体M4修复压缩载荷下软骨损伤的实验研究
-
批准号:JCZRLH202500789
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:
-
依托单位:
搭载硝呋齐特前药/SPP1siRNA复合脂质体纳米制剂的巨噬细胞仿生递送系统用于重塑肿瘤免疫抑制性微环境及机制研究
-
批准号:QN25H160070
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:杨振涛
-
依托单位:
外泌体的siRNA胞内原位封装技术的开发
及胰腺癌基因靶向治疗研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2025
-
负责人:杨成彬
-
依托单位:
负载Rspo2siRNA的细胞外囊泡缓解软骨下骨重塑治疗骨关节炎的作用及机制
-
批准号:QN25H180033
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:孙丰田
-
依托单位: